Literature DB >> 23650163

Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Guanpingsheng Luo1, Teclegiorgis Gebremariam, Hongkyu Lee, Samuel W French, Nathan P Wiederhold, Thomas F Patterson, Scott G Filler, Ashraf S Ibrahim.   

Abstract

Mucormycosis is a life-threatening fungal infection almost uniformly affecting diabetics in ketoacidosis or other forms of acidosis and/or immunocompromised patients. Inhalation of Mucorales spores provides the most common natural route of entry into the host. In this study, we developed an intratracheal instillation model of pulmonary mucormycosis that hematogenously disseminates into other organs using diabetic ketoacidotic (DKA) or cyclophosphamide-cortisone acetate-treated mice. Various degrees of lethality were achieved for the DKA or cyclophosphamide-cortisone acetate-treated mice when infected with different clinical isolates of Mucorales. In both DKA and cyclophosphamide-cortisone acetate models, liposomal amphotericin B (LAmB) or posaconazole (POS) treatments were effective in improving survival, reducing lungs and brain fungal burdens, and histologically resolving the infection compared with placebo. These models can be used to study mechanisms of infection, develop immunotherapeutic strategies, and evaluate drug efficacies against life-threatening Mucorales infections.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23650163      PMCID: PMC3697351          DOI: 10.1128/AAC.00313-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  60 in total

Review 1.  Diabetes and the gut.

Authors:  J H Scarpello; G E Sladen
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

2.  Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro.

Authors:  Ashraf S Ibrahim; Brad Spellberg; Valentina Avanessian; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  Effects of iron and desferrioxamine on Rhizopus infection.

Authors:  F Abe; H Inaba; T Katoh; M Hotchi
Journal:  Mycopathologia       Date:  1990-05       Impact factor: 2.574

4.  In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.

Authors:  A R Waldorf; S M Levitz; R D Diamond
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

5.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes.

Authors:  Y Zou; G Zong; Y H Ling; M M Hao; G Lozano; W K Hong; R Perez-Soler
Journal:  J Natl Cancer Inst       Date:  1998-08-05       Impact factor: 13.506

7.  Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.

Authors:  J R Boelaert; J Van Cutsem; M de Locht; Y J Schneider; R R Crichton
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

Review 8.  Improved outcome of zygomycosis in patients with hematological diseases?

Authors:  B Gleissner; A Schilling; I Anagnostopolous; I Siehl; E Thiel
Journal:  Leuk Lymphoma       Date:  2004-07

Review 9.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

10.  Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.

Authors:  A R Waldorf; N Ruderman; R D Diamond
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

View more
  31 in total

1.  Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model.

Authors:  Thomas Brunet; Kévin Brunet; Grégory Jouvion; Estelle Cateau; Sandrine Marchand; Blandine Rammaert
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.

Authors:  Teclegiorgis Gebremariam; Sondus Alkhazraji; Clara Baldin; Laura Kovanda; Nathan P Wiederhold; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Clinical Analysis of Diabetic Combined Pulmonary Mucormycosis.

Authors:  Yu-Hong Li; Peng Sun; Jian-Chao Guo
Journal:  Mycopathologia       Date:  2017-06-30       Impact factor: 2.574

Review 4.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

5.  PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis.

Authors:  Clara Baldin; Sameh S M Soliman; Heewon H Jeon; Sondus Alkhazraji; Teclegiorgis Gebremariam; Yiyou Gu; Vincent M Bruno; Oliver A Cornely; Helen L Leather; Michele W Sugrue; John R Wingard; David A Stevens; John E Edwards; Ashraf S Ibrahim
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

6.  Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.

Authors:  Bianca Schulze; Günter Rambach; Volker U Schwartze; Kerstin Voigt; Katja Schubert; Cornelia Speth; Ilse D Jacobsen
Journal:  Virulence       Date:  2017-08-24       Impact factor: 5.882

7.  CotH3 mediates fungal invasion of host cells during mucormycosis.

Authors:  Teclegiorgis Gebremariam; Mingfu Liu; Guanpingsheng Luo; Vincent Bruno; Quynh T Phan; Alan J Waring; John E Edwards; Scott G Filler; Michael R Yeaman; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

8.  Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Abdullah Alqarihi; Priya Uppuluri; Nkechi Azie; John E Edwards; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

9.  Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Authors:  Russell E Lewis; Nathaniel D Albert; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

10.  VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Authors:  Teclegiorgis Gebremariam; Nathan P Wiederhold; Annette W Fothergill; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.